



(<http://www.defense.gov/>)

C O R O N A V I R U S : OPERATION WARP SPEED TIMELINE

Using the resources of the Federal Government and the U.S. private sector, Operation Warp Speed (OWS) will accelerate the testing, supply, development, and distribution of safe and effective vaccines, diagnostics, and therapeutics to counter COVID-19 by January 2021.



[CORONAVIRUS SPOTLIGHT\(/EXPLORE/SPOTLIGHT/CORONAVIRUS/\)](/EXPLORE/SPOTLIGHT/CORONAVIRUS/)

[OPERATION WARP SPEED \(/EXPLORE/SPOTLIGHT/CORONAVIRUS/OPERATION-WARP-SPEED/\)](/EXPLORE/SPOTLIGHT/CORONAVIRUS/OPERATION-WARP-SPEED/)

Jan. 12, 2021

The Department of Health and Human Services (HHS) and the Department of Defense (DOD) announces the purchase of 1.25 million additional treatment courses of Regeneron's investigational monoclonal antibody therapeutic to be delivered in the first half of 2021 to treat non-hospitalized, high-risk COVID-19 patients

[Skip to main content \(Press Enter\).](#)



Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed; Dr. Moncef Slaoui, chief advisor to Operation Warp Speed; Secretary of Health and Human Services Alex M. Azar II; and Dr. Robert R. Redfield, Director of the Centers for Disease Control and Prevention brief the news media on Operation Warp Speed

Jan. 6, 2021

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed; Dr. Moncef Slaoui, chief advisor to Operation Warp Speed; and Health and Human Services Secretary Alex M. Azar II brief the media on the progress of Operation Warp Speed

Dec. 30, 2020

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed, and Dr. Moncef Slaoui, chief advisor to Operation Warp Speed, brief the media on Operation Warp Speed and COVID-19 vaccine distribution

Dec. 28, 2020

Novavax begins Phase 3 clinical trials

Dec. 23, 2020

The U.S. Department of the Health and Human Services and DOD jointly announce an agreement with Merck to continue the development and large-scale manufacturing of investigational COVID-19 treatment MK-7110

[Skip to main content \(Press Enter\).](#)



U.S. DEPT. OF DEFENSE
The Administration (http://www.defense.gov/)

The Administration announces that it will purchase an additional 100 million doses of COVID-19 vaccine from Pfizer through the U.S. Department of Health and Human Services and DOD

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed; Dr. Moncef Slaoui, chief advisor to Operation Warp Speed; and Health and Human Services Secretary Alex M. Azar II brief the media on the progress of Operation Warp Speed

Dec. 21, 2020

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed; Dr. Moncef Slaoui, chief advisor to Operation Warp Speed; and Health and Human Services Secretary Alex M. Azar II brief the media on the progress of Operation Warp Speed

Dec. 19, 2020

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed, briefs the media on Operation Warp Speed and COVID-19 vaccine distribution

Dec. 18, 2020

U.S. Food and Drug Administration issues an Emergency Use Authorization for Moderna's COVID-19 vaccine

Dec. 16, 2020

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed; Dr. Moncef Slaoui, chief advisor to Operation Warp Speed; and

Skip to main content (Press Enter).



Speed, Dr. Moncef Slaoui, chief advisor to Operation Warp Speed, and Health and Human Services Secretary Alex M. Azar II brief the media on Operation Warp Speed and COVID-19 vaccine distribution

Dec. 14, 2020

Army Gen. Gustave F. Perna, chief operations officer for Operation Warp Speed; Health and Human Services Secretary Alex M. Azar II; and Dr. Moncef Slaoui, chief advisor for OWS, conduct a briefing on Operation Warp Speed beginning nationwide vaccine distribution

Dec. 12, 2020

Army Gen. Gustave F. Perna, chief operations officer for Operation Warp Speed, conducts a briefing on Operation Warp Speed planning for nationwide vaccine distribution

Dec. 11, 2020

DOD purchases an additional 100 million doses of Moderna's COVID-19 vaccine

U.S. Food and Drug Administration issues an Emergency Use Authorization to Pfizer for its COVID-19 vaccine

Nov. 24, 2020

Army Gen. Gustave F. Perna, chief operations officer for Operation Warp Speed, Health and Human Services Secretary Alex M. Azar II and Dr. Moncef Slaoui, chief advisor for OWS, conduct a briefing on Operation Warp Speed

[Skip to main content \(Press Enter\).](#)



Congressional/media engagement on Emergency Use Authorization of Regeneron's investigational monoclonal antibody therapeutic cocktail

Nov. 21, 2020

U.S. Food and Drug Administration issues an Emergency Use Authorization for Regeneron's investigational monoclonal antibody therapeutic cocktail comprised of the drugs casirivimab and imdevimab for treatment of non-hospitalized patients with mild or moderate confirmed cases of COVID-19 at high risk of hospitalization

Nov. 18, 2020

Army Gen. Gustave F. Perna, chief operations officer for Operation Warp Speed, Health and Human Services Secretary Alex M. Azar II and Dr. Moncef Slaoui, chief advisor for OWS, conduct a briefing on Operation Warp Speed

Nov. 12, 2020

The U.S. government partnered with large chain pharmacies and networks covering approximately 60 percent of pharmacies throughout the United States, Puerto Rico, and the U.S. Virgin Islands to maximize access to COVID-19 vaccines

Nov. 10, 2020

Congressional/media engagement on OWS vaccine distribution and therapeutics

[Skip to main content \(Press Enter\).](#)



U.S. DEPT OF DEFENSE (http://www.defense.gov/)

Nov. 9, 2020

U.S. Food and Drug Administration issues an Emergency Use Authorization for Eli Lilly's COVID-19 investigational antibody therapeutic

Oct. 28, 2020

The Department of Health and Human Services and DOD announce an agreement with Eli Lilly and Company to purchase 300,000 doses of the company's COVID-19 investigational antibody therapeutic for \$375 million. These doses will be available for patient care if the U.S. Food and Drug Administration authorizes use of the therapeutic, as outlined in agency guidance

Oct. 23, 2020

AstraZeneca resumes COVID-19 Phase 3 vaccine clinical trials in the United States after the FDA and an independent safety review board completed an examination of all safety data from trials globally and concluded it was safe to resume

Congressional/media engagement on OWS vaccine distribution and minority enrollment in clinical trials

Oct. 19, 2020

All 64 jurisdictions submitted initial COVID-19 vaccine distribution plans to the Centers for Disease Control and Prevention, a significant milestone in the ongoing collaboration between the federal government and

Skip to main content (Press Enter).

jurisdictions to prepare for delivery of a safe, effective vaccine to the



American people

DEPARTMENT OF DEFENSE

(<http://www.defense.gov/>)

Oct. 16, 2020

The Department of Health and Human Services and DOD announce agreements with CVS and Walgreens to provide COVID-19 vaccine with no out-of-pocket costs to protect vulnerable Americans in long-term care facilities nationwide once vaccines are available and recommended for them

Oct. 13, 2020

\$31 million agreement with Cytiva to expand manufacturing capacity for products essential in producing COVID-19 vaccines, such as liquid and dry powder cell culture media, cell culture buffers, mixer bags, and XDR bioreactors

Oct. 9, 2020

\$486 million agreement with AstraZeneca for late-stage development and large-scale manufacturing of the company's COVID-19 investigational prophylaxis product, a cocktail of two monoclonal antibodies, that may help treat or prevent the coronavirus that causes COVID-19

Congressional/media engagement on OWS vaccine distribution

Sept. 23, 2020

Johnson & Johnson begins Phase 3 clinical trials

Sept. 10, 2020



U.S.
DEPT OF
DEFENSE

(<http://www.defense.gov/>)

The Department of Health and Human Services and DOD release two documents outlining the Administration's strategy to deliver safe and effective COVID-19 vaccine doses to Americans as quickly and reliably as possible. The documents provide a strategic distribution overview (https://media.defense.gov/2020/Sep/16/2002498509/-1/-1/1/OPERATION_WARP_SPEED_STRATEGY_FOR_DISTRIBUTING_COVID19_VACCINE.PDF) along with an interim playbook (https://media.defense.gov/2020/Sep/16/2002498510/-1/-1/1/COVID19_VACCINATION_PROGRAM_PLAYBOOK.PDF) for jurisdiction operations

Congressional/media engagement on OWS vaccines

Sept. 8, 2020

AstraZeneca pauses clinical trials due to an unexpected adverse event in a study participant in the Phase 2/3 trial in the UK. AstraZeneca is working with the FDA to facilitate review of the information and the agency will decide when the U.S. trial can resume

Sept. 3, 2020

As part of the Operation Warp Speed goal to deliver safe and effective vaccines and therapeutics by January 2021, five DOD medical treatment facilities are identified for Phase 3 COVID-19 vaccine trials. The selected sites are located in the National Capital Region, San Antonio and San Diego

Aug. 29, 2020

AstraZeneca begins Phase 3 clinical trials

[Skip to main content \(Press Enter\).](#)



(<http://www.defense.gov/>)

Congressional/media engagement on OWS vaccine distribution

Aug. 23, 2020

U.S. Food and Drug Administration issues an Emergency Use Authorization for convalescent plasma

Aug. 17, 2020

\$106 million contract with Ology Bioservices Inc. to reserve production capacity of more than 180 million doses of COVID-19 medical countermeasures

Aug. 14, 2020

CDC selects McKesson Corporation to support distribution of COVID-19 vaccines and related supplies

Aug. 13, 2020

Congressional/media engagement on OWS vaccine prioritization

Aug. 11, 2020

\$1.5 billion agreement with Moderna to support the large-scale manufacture and delivery of a vaccine candidate

Aug. 5, 2020

Skip to main content (Press Enter).

U.S.
DEFENSE

\$1.95 billion agreement with Johnson & Johnson (Janssen) to support the large-scale manufacturing and delivery of a vaccine candidate

Aug. 4, 2020

\$160 million awarded to Grand River Aseptic Manufacturing Inc. for domestic aseptic fill and finish manufacturing capacity for critical vaccines and therapeutics

July 31, 2020

\$2 billion agreement with Sanofi and GlaxoSmithKline to support the advanced development, including clinical trials and large-scale manufacturing, of a vaccine candidate

July 30, 2020

Congressional/media engagement on OWS vaccines

July 27, 2020

Moderna and Pfizer begin Phase 3 clinical trials

Texas A&M University and FUJIFILM announce a task order with Texas A&M University and FUJIFILM to advance domestic manufacturing capabilities and capacity for a potential COVID-19 vaccine

July 22, 2020

\$1.95 billion agreement with Pfizer for the large-scale manufacturing and nationwide distribution of 100 million doses of their vaccine candidate

Skip to main content (Press Enter).

nationwide distribution of 100 million doses of their vaccine candidate



U.S.
DEPT OF
DEFENSE (http://www.defense.gov/)

July 13, 2020

Congressional/media engagement on OWS vaccines

July 7, 2020

\$1.6 billion agreement to support the large-scale manufacturing of
Novavax's vaccine candidate

July 2, 2020

GEN Gustave Perna is Senate-confirmed to serve as chief operating officer

June 18, 2020

GEN Gustave Perna confirmation hearing

June 15, 2020

Congressional/media engagement on OWS vaccines


June 11, 2020

\$143 million agreement with SiO2 Materials Science to ramp up capacity
to produce the company's glass-coated plastic container

June 9, 2020

\$204 million agreement with Corning to expand the domestic

Skip to main content (Press Enter)



manufacturing capacity to produce approximately 164 million Valor Glass
vials per year (<http://www.defense.gov/>)

June 1, 2020

Emergent BioSolutions announces a task order to advance domestic manufacturing capabilities and capacity for a potential COVID-19 vaccine as well as therapeutics

May 21, 2020.

\$1.2 billion agreement in support for AstraZeneca's candidate vaccine

May 15, 2020

White House announces Operation Warp Speed, or OWS

May 12, 2020.

\$138 million contract with ApiJect for more than 100 million prefilled syringes for distribution across the United States by year-end

April 16, 2020.

\$483 million agreement in support available for Moderna's candidate vaccine, which began Phase 1 trials on March 16, 2020, and received a fast-track designation from the U.S. Food & Drug Administration

March 30, 2020

Skip to main content (Press Enter) **\$456 million for Johnson & Johnson's candidate vaccine**



U.S.
DEPT OF
DEFENSE (http://www.defense.gov/)

UPDATES

FAQs

DOD is collaborating closely with public and private sector partners to provide an unprecedented response to the coronavirus outbreak. Our crucial support includes assistance for the accelerated development and rapid distribution of a safe, effective vaccine or vaccines and therapeutics for COVID-19. Below is information on this American vaccine effort.

LEARN MORE

(/EXPLORE/SPOTLIGHT/CORONAVIRUS/OPERATION-WARP-SPEED/OPERATION-WARP-SPEED-FAQ/)

Latest Cure Progress

Operation Warp Speed

Using the resources of the federal government and the U.S. private sector, Operation Warp Speed (OWS) will accelerate the testing, supply, development, and distribution of safe and effective vaccines, therapeutics, and diagnostics to counter COVID-19 by January 2021.

[Skip to main content \(Press Enter\).](#)



U.S. DEPT OF DEFENSE

SPOTLIGHT
(http://www.defense.gov/)
(/EXPLORE/SPOTLIGHT/CORONAVIRUS/OPERATION-WARP-SPEED/)

Latest Guidance and Information

Coronavirus: DOD Response

The Defense Department is working closely with the Department of Health and Human Services and the State Department to provide support in dealing with the coronavirus outbreak.

SPOTLIGHT (/EXPLORE/SPOTLIGHT/CORONAVIRUS/)


DEFENSE.GOV

HELPFUL LINKS

RESOURCES

POPULAR

Skip to main content (Press Enter).



SUBSCRIBE

(HTTPS://PUBLIC.GOVDELIVERY.COM/ACCOUNTS/USDOD/SUBSCRIBER/NEW)